5-cyano-2-iodobenzoyl chloride | 219842-00-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 5-cyano-2-iodobenzoyl chloride
• CAS: 219842-00-9
• 化学式: C₈H₃ClINO
• 分子量: 291.475
• InChiKey: SAGPFZIKUPVAER-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  40.9
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  5-cyano-2-iodobenzoyl chloride 在 palladium bis[bis(diphenylphosphino)ferrocene] dichloride 、 碳酸氢钠 、 N,N-二异丙基乙胺 作用下， 以 二氯甲烷 、 水 、 乙腈 为溶剂， 反应 10.0h， 生成 4-(3-fluorophenyl)-3-[2-(2-methylpyridin-4-yl)-2H,4H,5H,6H-pyrrolo[3,4-c]pyrazole-5-carbonyl]benzonitrile
  参考文献：
  名称：

  [EN] SUBSTITUTED 2,4,5,6-TETRAHYDROPYRROLO[3,4-C] PYRAZOLE AND 4,5,6,7-TETRAHYDRO-2H-PYRAZOLO [4,3-C] PYRIDINE COMPOUNDS AS GLYT1 INHIBITORS
  [FR] COMPOSÉS DE 2,4,5,6-TÉTRAHYDROPYRROLO[3,4-C] PYRAZOLE ET 4,5,6,7-TÉTRAHYDRO-2 H-PYRAZOLO [4,3-C] PYRIDINE UTILISÉS COMME INHIBITEURS DE GLYT1

  摘要：

  公开号：

  WO2015164520A4
• 作为产物：
  描述：

  5-氰基-2-碘苯甲酸 在 氯化亚砜 作用下， 生成 5-cyano-2-iodobenzoyl chloride
  参考文献：
  名称：

  [EN] PPARG INVERSE AGONISTS AND USES THEREOF
  [FR] AGONISTES INVERSES DE PPARG ET LEURS UTILISATIONS

  摘要：

  Provided are compounds of Formula (I):and pharmaceutically acceptable salts and compositions thereof, which are useful for treating a variety of conditions associated with PPARG.

  公开号：

  WO2023172846A1

文献信息

• WO2006/128852
  申请人：——

  公开号：——

  公开（公告）日：——
• COMPOUNDS
  申请人：AstraZeneca UK Limited

  公开号：EP1000064A1

  公开（公告）日：2000-05-17
• SUBSTITUTED 2,4,5,6-TETRAHYDROPYRROLO[3,4-C]PYRAZOLE AND 4,5,6,7-TETRAHYDRO-2H-PYRAZOLO [4,3-C]PYRIDINE COMPOUNDS AS GLYT1 INHIBITORS
  申请人：Dart Neuroscience (Cayman) Ltd

  公开号：EP3134406A1

  公开（公告）日：2017-03-01
• SUBSTITUTED 2,4,5,6-TETRAHYDROPYRROLO[3,4-C]PYRAZOLE AND 4,5,6,7-TETRAHYDRO-2H-PYRAZOLO[4,3-C]PYRIDINE COMPOUNDS AS GLYT1 INHIBITORS
  申请人：DART NEUROSCIENCE (CAYMAN) LTD.

  公开号：US20170044167A1

  公开（公告）日：2017-02-16

  The invention provides a chemical entity of Formula (I), wherein R 1 , R 2 , R 3 , R 4 , R 5 and X have any of the values described herein, and compositions comprising such chemical entities; methods of making them; and their use in a wide range of methods, including metabolic and reaction kinetic studies; detection and imaging techniques; radioactive treatments; modulating and treating disorders mediated by GlyT1 activity; treating neurological disorders, CNS disorders, dementia, neurodegenerative diseases, and trauma-dependent losses of function; treating stroke, including cognitive and motor deficits during stroke rehabilitation; facilitating neuroprotection and neurorecovery; enhancing the efficiency of cognitive and motor training, including animal skill training; and treating other disorders, including pain and alcohol-dependence.
• US6083952A
  申请人：——

  公开号：US6083952A

  公开（公告）日：2000-07-04